Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2001-03-16
2004-09-28
Helms, Larry R. (Department: 1692)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S387100, C530S387300
Reexamination Certificate
active
06797492
ABSTRACT:
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A-1C
. Solvent exposure of sidechains of framework residues in KOL and J539 Fvs and the residues which occur most frequently at these positions in the various human VH subgroups.
FIGS. 2A and 2B
. Solvent exposure of sidechains of framework residues in KOL VL and the residues which occur most frequently at these positions in the various human V-lambda subgroups.
FIGS. 3A and 3B
. Solvent exposure of sidechains of framework residues in J539 VL and the residues which occur most frequently at these positions in the various human V-kappa subgroups.
FIG.
4
. Primers used to isolate DNA encoding murine kappa light chain variable region and murine IgG2a heavy chain variable region using PCR. Oligodeoxynucleotides used as PCR primers to generate a shortened IgG4 heavy chain. Oligodeoxynucleotides used in PCR to re-engineer the thymidine kinase (TK) promoter to facilitate the expression of the neomycin resistance gene. Oligodeoxynucleotide primers used in PCR to clone the IgH enhancer sequence. Oligodeoxynucleotides used as PCR primers to generate a human kappa light chain constant region.
FIG.
5
. Oligodeoxynucleotides used in the construction of the “veneered” 1B4 heavy and light chain variable regions plus those necessary to fuse the human signal and intronic sequenceds onto these variable regions.
FIG.
6
. PCR-recombination strategy used in the veneering of the 1B4 kappa light chain variable region.
FIGS. 7A-7C
. Outline of the insertion of the “veneered” kappa light chain variable region and kappa constant region into the light chain expression vector.
FIG.
8
. PCR-recombination strategy used in the veneering of the 1B4 heavy chain variable region.
FIGS. 9A
an
9
B. Outline of the insertion of the “veneered” heavy chain variable region into the heavy chain expression vector.
FIGS. 10A and 10B
. Outline of the insertion of neomycin selectable expression vector.
FIGS. 11A-10C
. Outline of the insertion of hygromycin selectable expression vector.
FIG.
12
. Amino acid sequence compleition of the “veneered”-1B4, murine 1B4 and human Gal heavy chain variable regions and the “veneered” 1B4, murine 1B4 and human Len kappa light chain variable regions. Check marks idicate the individual amino acid residues converted.
FIG.
13
. Competitive binding assay of native murine 1B4 (open diamonds) and recombinant “veneered” 1B4 (closed diamonds).
FIG.
14
. Inmunogenicity of a veneered murine antibody in Rhesus monkeys is shown.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 239400 (1987-09-01), None
patent: 255694 (1988-02-01), None
patent: 274394 (1988-07-01), None
patent: 328404 (1989-06-01), None
patent: 323806 (1989-07-01), None
patent: 327000 (1989-08-01), None
patent: 332424 (1989-09-01), None
patent: 434257 (1991-06-01), None
patent: 438312 (1991-07-01), None
patent: 2 188 638 (1987-10-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10742 (1991-07-01), None
patent: WO 91/11198 (1991-08-01), None
patent: WO 91/11534 (1991-08-01), None
Novotny et al., PNAS 83:226-30, 1986.*
Hunter, W.M. et al., Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity, 1962, Nature, 194, pp. 495-496 (cumulative).
English, D. et al., Single Separation of Red Blood Cells: Granulocytes and Mononuclear Leukocytes on Discontinuous Density Gradents of Ficoll-Hypaque, 1974, J. Immunological Methods, 5, pp. 249-252 (cumulative).
Bernstein, F.C. et al., The Protein Data Bank: A Computer-based Archival File for Macromolecular Structures, 1977, J. Mol. Biol., 112, pp. 535-542 (cumulative).
Rodbard, D. et al., Improved Curve-Fitting, Parallelism Testing, Characterization Of Sensitivity And Specificity, Validation, And Optimization For Radioligand Assays, 1978, In: Radioimmunoassay & Related Procedures In Medicine, International Atomic Agency, Vienna, vol. 1, pp. 469-504 (cumulative).
Chirgwin, J. et al., Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease, 1979, Biochemistry, 18, pp. 5294-5299 (cumulative).
Flanagan, J.G. et al., Arrangement of human immnoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing &ggr;, &egr; and &agr; genes, 1982, Nature, 300, pp. 709-813 (cumulative).
Daugherty, B.L et al.,Polymerase chain reaction facilitates the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins, 1991, Nucleic Acids Research, 19, pp. 2471-2476 (cumulative).
Beatty, P.G. et al., Definition of a Common Leukocyte Cell-Surface Antigen )Lo95-150) Associated with Diverse Cell-Mediated Immune Functions, 1983, J. Immunol., 131, pp. 2913-1918 (cumulative).
Sanchez-Madrid, F. et al., A Human Leukocyte Differentiation Antigen Family With Distinct &agr;-Subunits and a Common B-Subunit, 1983, J. Exp. Med. 158, pp. 1785-1803 (cumulative).
VanVoorhis, W.C. et al., Specific Antimononuclear Phagocyte Monoclonal Antibodies, 1983, J. Exp. Med., 158, pp. 126-145 (cumulative).
Wright, S.D. et al., Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies (cumulative).
Gritz, L et al., Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B phosphotransferase gene and its expression inEscherichia coliandSaccharomyces cerevisiae,1983, Gene, 25, pp. 179-188 (cumulative).
Berkner, K.L. et al., Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant, 1985, Nucleic Acids, Res., 13, pp. 841-857 (cumulative).
Riechmann, L. et al., Reshaping human antibodies for therapy, 1988, Nature, 332, pp. 323-327 (cumulative).
LoBuglio, A.F. et al., Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response, 1989, Proc. Nat'l Acad. Sci. USA, 86, pp. 4220-4224 (cumulative).
Sheriff, S., Antibody-Antigen Complexes1, 1990, Annu. Rev. Biochem., 59, pp. 439-473 (cumulative).
Padan, E., On the Nature of Antibody Combining Sites: Unusual Structural Features That May Confer on These Sites an Enhanced Capacity for Binding Ligands, 1990, Proteins: Struc., Funct., Genet., 7, pp. 112-124 (cumulative).
Hakimi, J. et al., Reduce Immunogenicity And Improved Pharmacokinetics Of Humanized Anti-Tac In Cynomolgus Monkeys, 1991, J. Immunol., 147, pp. 1352-1359 (cumulative).
Lo, S.K. et al., Transient Adhesion of Neutrophils To Endothelium, J. Exp. Med., 169, pp. 1779-1793 (cumulative).
Sequences of Proteins of Immunol. Int., 4th Edition, U.S. Dept. of Health and Human Services (cumulative).
Gorman, S.D. et al., Reshaping a therapeutic CD4 antibody, 1991, Proc. Nat'l. Acad. Sci., 88, pp. 4181-4185 (cumulative).
Padlan, E. et al., Modeling of Antibody Comining Sites,1991, Methods in Enzymology, 203, pp. 30-21 (cumulative).
Padlan, E., A Possible Procedure for Reducing The Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties, 1991, Molec. Immun., 28(4/5), pp. 489-498 (cumulative).
Verhoeyen, M. et al., Reshaping Human Antibodies: Grafting an Antilysozme Activity, 1988, Science, 239, pp. 1534-1536 (cumulative).
Queen, C. et al., A humanized antibody that binds to the interleukin 2 receptor, 1989, PNAS, 86, pp. 10029-10033 (cumulative).
Bolger, M.B., et al., Computer Modeling of Combining Site Structure of Anti-hapten Monoclonal Antibodies, 1991, Methods in Enzy., 203, pp. 21-45 (cumulative).
Lewin, ‘When Does Homology Mean Something else’, Science 237: 1570 (1987).
Reeck et al. ‘Homology in Proteins and Nucleic Acids . . . out of it’, Cell, vol. 50, p 667, 1987.
Creighton Proteins Structure and Molecular Principals, WH Freeman & Co.NY pp 93-94, 1983.
Creighton, ‘Experimental Studies of Protein Folding and Unfolding’, Biophys. Mole/Bio, vol. 33, pp 231-233, 1975.
Burgess et al. ‘Possible Dissociation of the Heparin-binding . . . by Site directed Mutagenesis of a Single Lysine Residue’, J. of Cell Biol., vol. 111, pp 2129-2138, 1990.
Lazar
Daugherty Bruce L.
Mark, III George E.
Padlan Eduardo A.
Helms Larry R.
Merck & Co. , Inc.
Tribble Jack L.
Xu Yang
LandOfFree
Method for reducing the immunogenicity of antibody variable... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing the immunogenicity of antibody variable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing the immunogenicity of antibody variable... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3195767